US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

The following is a summary of “Validity of diagnosis codes to identify a dermatomyositis cohort from electronic health records,” published in the January 2025 issue of Dermatology by Silberzweig et al ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

It is not known whether Octagam 10% can cause fetal harm when administered ... where she serves as Co-Director of the Myositis Center and Director of Clinical Trials. She earned her undergraduate ...

Trusted source of information on Fibromyalgia that includes articles, news, videos, animations, quizzes, calculators and drugs.

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Myopathic (myo = muscle, pathy = disease) conditions can include polymyositis, dermatomyositis, inclusion body myositis, and various myopathies due to metabolic, congenital, and endocrine causes.

There is an underdiagnosed condition called statin-induced autoimmune myopathy. It can take years to show up and can be hard to treat.

But, unlike others on the plane, Parsons isn’t taking a vacation or going to visit family. Alongside the usual collection of clothes, toiletries and knick-knacks, he packs more than 100 baseball ...